Kosin Med J.  2022 Mar;37(1):18-26. 10.7180/kmj.22.017.

Adverse events following vaccination against coronavirus disease 2019

• Jeon M
• Jin S
• Lee JY

• KMID: 2527691
• DOI: http://doi.org/10.7180/kmj.22.017

Abstract

To overcome the coronavirus disease 2019 (COVID-19) pandemic, large-scale vaccination is proceeding worldwide. As of December 23, 2021, 10 novel vaccines against COVID-19 had been validated for use by the World Health Organization (WHO), including BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), AZD1222 (AstraZeneca), and Ad26.COV2.S (Janssen). These novel vaccines against COVID-19 showed acceptable safety profiles in randomized clinical trials. Most adverse events following immunization (AEFIs) associated with these novel vaccines ranged from mild to moderate and improved within a few days after administration. However, serious adverse events associated with vaccines that were not observed in the clinical trials were reported in real-world data. Adverse events of special interest include not only anaphylaxis or neurologic disorders (such as Guillain-Barré syndrome, transverse myelitis, or seizure) but also myocarditis or pericarditis associated with the messenger RNA (mRNA) vaccines and thrombosis with thrombocytopenia syndrome associated with the adenovirus-vector vaccines. Although several fatal cases of serious AEFIs that may have been related to vaccination have been reported, it is recommended to continue vaccination because the benefits of vaccines’ preventive effects against COVID-19 outweigh the risks of rare serious adverse events. Long-term monitoring of various AEFIs and sharing of clinical experiences are necessary for safe and efficient large-scale vaccination.

Keyword

Adverse drug events; COVID-19; Vaccination

Reference

References

1. World Health Organization (WHO). WHO coronavirus (COVID-19) dashboard [Internet]. Geneva: WHO;c2022. [cited 2022 Jan 31]. https://covid19.who.int/.

2. World Health Organization (WHO). Status of COVID-19 vaccines within WHO EUL/PQ evaluation process [Internet]. Geneva: WHO;c2021. [cited 2022 Feb 2]. https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_23Dec2021.pdf.

3. U.S. Food & Drug Administration. Learn more about COVID-19 vaccines from the FDA [Internet]. Silver Spring: U.S. Food & Drug Administration;c2022. [cited 2022 Feb 1]. https://www.fda.gov/consumers/consumer-updates/learn-more-about-covid-19-vaccines-fda.

4. World Health Organization (WHO). Global manual on surveillance of adverse events following immunization, 2016 update. Geneva: WHO;c2014. [cited 2022 Feb 1]. https://apps.who.int/iris/handle/10665/206144.

5. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021; 384:403–16.

6. Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021; 384:2187–201.

7. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383:2603–15.

8. Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397:99–111.

9. Vaccine Adverse Event Reporting System (VAERS). VAERS data sets [Internet]. Rockville: VAERS;c2022. [cited 2022 Feb 1]. https://vaers.hhs.gov/data/datasets.html.

10. Korea Disease Control and Prevention Agency (KDCA). Weekly report of adverse reactions after COVID-19 vaccination, 47th weeks [Internet]. Cheongju: KDCA;c2022. [cited 2022 Mar 6]. Available from: https://ncv.kdca.go.kr/board.es?mid=a12609020000&bid=0036&tag=&act=view&list_no=664.

11. Medicines and Healthcare products Regulatory Agency (MHRA). Coronavirus vaccine-weekly summary of Yellow Card reporting [Internet]. London: MHRA;c2022. [cited 2022 Feb 3]. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting.

12. Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020; 383:2439–50.

13. Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021; 385:1761–73.

14. Doroftei B, Ciobica A, Ilie OD, Maftei R, Ilea C. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics (Basel). 2021; 11:579.

15. Sellaturay P, Nasser S, Ewan P. Polyethylene glycol-induced systemic allergic reactions (anaphylaxis). J Allergy Clin Immunol Pract. 2021; 9:670–5.

16. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021; 385:1078–90.

17. Fazlollahi A, Zahmatyar M, Noori M, Nejadghaderi SA, Sullman MJ, Shekarriz-Foumani R, et al. Cardiac complications following mRNA COVID-19 vaccines: a systematic review of case reports and case series. Rev Med Virol. 2021 Dec 17 [Epub]. https://doi.org/10.1002/rmv.2318.

18. Korea Disease Control and Prevention Agency (KDCA). Weekly report of adverse reactions after COVID-19 vaccination, 51st weeks [Internet]. Cheongju: KDCA;c2022. [cited 2022 Mar 6]. Available from: https://ncv.kdca.go.kr/board.es?mid=a12609020000&bid=0036&tag=&act=view&list_no=713.

19. European Medicines Agency (EMA). Assessment report: COVID-19 Vaccine Moderna [Internet]. Amsterdam: EMA;c2021. [cited 2022 Feb 6]. https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf.

20. Centers for Disease Control and Prevention (CDC). Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine–United States, December 21, 2020–January 10, 2021 [Internet]. Atlanta: CDC;c2021. [cited 2022 Feb 1]. https://www.cdc.gov/mmwr/volumes/70/wr/mm7004e1.htm.

21. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022; 28:410–22.

22. McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021; 85:46–55.

23. Rice SM, Ferree SD, Mesinkovska NA, Kourosh AS. The art of prevention: COVID-19 vaccine preparedness for the dermatologist. Int J Womens Dermatol. 2021; 7:209–12.

24. Osmond A, Kenny B. Reaction to dermal filler following COVID-19 vaccination. J Cosmet Dermatol. 2021; 20:3751–2.

25. Korea Disease Control and Prevention Agency (KDCA). COVID-19 Vaccination Guideline in the Republic of Korea (update February 14, 2022) [Internet]. Cheongju: KDCA;c2022. [cited 2022 Feb 28]. https://ncv.kdca.go.kr/board.es?mid=a12101000000&bid=0031#.

26. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021; 396:1979–93.

27. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396:467–78.

28. Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021; 8:e568–80.

29. O'Reilly P. A Phase III study to investigate a vaccine against COVID-19 [Internet]. ISRCTN registry;c2020. [cited 2022 Mar 6]. https://www.isrctn.com/ISRCTN89951424.

30. World Health Organization (WHO). COVID-19 vaccines: safety surveillance manual [Internet]. Geneva: WHO;c2020. [cited 2022 Feb 28]. https://apps.who.int/iris/handle/10665/338400.

31. Stone CA Jr, Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 2019; 7:1533–40.

32. Schultz NH, Sorvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021; 384:2124–30.

33. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021; 384:2092–101.

34. Douxfils J, Favresse J, Dogne JM, Lecompte T, Susen S, Cordonnier C, et al. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thromb Res. 2021; 203:163–71.

35. Medicines and Healthcare products Regulatory Agency (MHRA). MHRA issues new advice, concluding a possible link between COVID-19 vaccine AstraZeneca and extremely rare, unlikely to occur blood clots. London: MHRA;c2021. [cited 2022 Feb 6]. https://www.gov.uk/government/news/mhra-issues-new-advice-concluding-a-possible-link-between-covid-19-vaccine-astrazeneca-and-extremely-rare-unlikely-to-occur-blood-clots.

36. European Medicines Agency (EMA). COVID-19 vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets [Internet]. Amsterdam: EMA;c2021. [cited 2022 Feb 6]. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots.

37. European Medicines Agency (EMA). COVID-19 vaccine safety update for VAXZEVRIA, Sep 8, 2021 [Internet]. Amsterdam: EMA;c2021. [cited 2022 Feb 15]. https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-8-september-2021_en.pdf.

38. Zuhorn F, Graf T, Klingebiel R, Schabitz WR, Rogalewski A. Postvaccinal encephalitis after ChAdOx1 nCov-19. Ann Neurol. 2021; 90:506–11.

39. Hsiao YT, Tsai MJ, Chen YH, Hsu CF. Acute transverse myelitis after COVID-19 vaccination. Medicina (Kaunas). 2021; 57:1010.

40. Druey KM, Parikh SM. Idiopathic systemic capillary leak syndrome (Clarkson disease). J Allergy Clin Immunol. 2017; 140:663–70.

41. Korean Ministry of Health and Welfare (MOHW). COVID-19 vaccination strategy and implementation plan of July [Internet]. Sejong: MOHW;c2021. [cited 2021 July 1]. Available from: http://ncov.mohw.go.kr/tcmBoardView.do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=5626&contSeq=5626&board_id=312&gubun=ALL.

42. Sulemankhil I, Abdelrahman M, Negi SI. Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: a case report and literature review. Cardiovasc Revasc Med. 2021 Aug 16 [Epub]. https://doi.org/10.1016/j.carrev.2021.08.012.

43. See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA. 2021; 325:2448–56.

44. Centers for Disease Control and Prevention (CDC). Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients—United States, April 2021 [Internet]. Atlanta: CDC;c2022. [cited 2022 Feb 17]. Available from: https://www.cdc.gov/mmwr/volumes/70/wr/mm7017e4.htm.

45. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Updates on thrombosis with thrombocytopenia syndrome (TTS)-Dec 16, 2021 [Internet]. Atlanta: CDC;c2022. [cited 2022 Feb 7]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-12-16/02-COVID-See-508.pdf.

46. Abbattista M, Martinelli I, Peyvandi F. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: thrombosis at unusual sites. J Thromb Haemost. 2021; 19:2554–8.

47. European Medicines Agency (EMA). COVID-19 vaccine safety update for COVID-19 VACCINE JANSSEN, Aug 11, 2021 [Internet]. Amsterdam: EMA;c2021. [cited 2022 Feb 17]. https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-11-august-2021_en.pdf.

48. European Medicines Agency (EMA). COVID-19 vaccine safety update for COVID-19 VACCINE JANSSEN, Oct 6, 2021 [Internet]. Amsterdam: EMA;c2021. [cited 2022 Feb 17]. https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-6-october-2021_en.pdf.

49. European Medicines Agency (EMA). COVID-19 vaccine safety update for COVID-19 VACCINE JANSSEN, Jul 14, 2021 [Internet]. Amsterdam: EMA;c2021. [cited 2022 Feb 17]. https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-14-july-2021_en.pdf.

50. Choi GJ, Baek SH, Kim J, Kim JH, Kwon GY, Kim DK, et al. Fatal systemic capillary leak syndrome after SARS-CoV-2 vaccination in patient with multiple myeloma. Emerg Infect Dis. 2021; 27:2973–5.